INTRODUCTION
============

Immunostimulated glial cells simultaneously produce nitric oxide (NO) and superoxide anion (O~2~^·-^) via expression and activation of inducible nitric oxide (iNOS) ([@B21]). NO and O~2~^·-^ rapidly react in a 1:1 stoichiometry to form a strong oxidant ONOO^-^ ([@B3]). ONOO^-^ has been found to play a critical role in tissue injury and appears to mediate many of the cytotoxic effects ([@B3]). Previously, we showed that immunostimulated astrocytes themselves became highly vulnerable to glucose deprivation (GD) ([@B6]; [@B5]). This enhanced vulnerability was attributed to the accumulation of ONOO^-^ due to the disruption of intracellular antioxidant system (i.e., decreased level of reduced glutathione) in glucose-deprived immunostimulated astrocytes ([@B6]; [@B7]; [@B4]; [@B5]). Expectedly, the ONOO^-^-releasing reagent 3-morpholinosydnonimine (SIN-1) also augmented the death of glucose-deprived astrocytes. Interestingly, we further found that the augmented death of immunostimulated or SIN-1-treated astrocytes under GD was dependent on the proliferative state of the astrocytes ([@B7]).

Activation of iNOS was reported to induce cytotoxicity in part by disturbing cell cycle progression ([@B11]; [@B15]). Apoptotic death of some cells can be blocked by coordinating the progression through the cell cycle and/or by preventing the inappropriate activation of cell cycle signalling pathways ([@B19]; [@B23]). Because proliferating immunostimulated astrocytes are much more vulnerable to GD, it is reasonable to think that the augmented death could be prevented by inhibition of cell cycle progression.

In the present study, therefore, we examined the possible cytoprotective effect of the DNA topoisomerase II inhibitor etoposide on peroxynitrite toxicity in proliferating astrocytes. Interestingly, the present results demonstrates for the first time that etoposide markedly blocks the augmented toxicity of ONOO^-^ in SIN-1-treated/glucose-deprived astrocytes by directly scavenging peroxynitrite, not by inhibiting cell cycle progression.

MATERIALS AND METHODS
=====================

Astrocyte cultures
------------------

Astrocytes were cultured from the prefrontal cortices of 2- to 5-day-old Sprague-Dawley rat pups as previously described ([@B6]) In brief, cells were dissociated by mild trypsinization (10 min at 37℃ with Dulbecco\'s modified Eagle medium (DMEM) containing 0.1% trypsin) and passed through a sterile nylon sieve (130µm pore size) into DMEM containing 10% heat-inactivated fetal bovine serum (FBS). Cells were then plated (about 50,000 cells/ml) onto poly-L-lysine (20µg/ml)-coated 75-cm^2^ culture bottles and maintained for one week in DMEM/F12 supplemented with 10% FBS. Astrocytes were then trypsinized, washed and re-plated in the growth medium onto poly-L-lysine (20µg/ml)-coated 48-well plates. Cells were used for the experiments 5 to 7 days later.

Measurement of lactate dehydrogenase
------------------------------------

Astrocytic injury and death was assessed by morphological examination of cells using phase-contrast microscopy and quantified by measuring the amount of lactate dehydrogenase (LDH) released into the bathing medium. Activity of LDH was measured using a diagnostic kit (Sigma Chemical Co., St. Louis, MO). In brief, NADH and pyruvate (0.1 w/v %) were added and the samples incubated at 37℃ for 30 min. The samples then were incubated with the coloring reagent for 20 min. The reaction was stopped by adding 0.4 N NaOH, and the activity (unit/ml) of LDH in each sample was calculated from the standard curve. Total LDH, which corresponds to complete astrocyte death, was measured in sister cultures frozen and thawed after the experiments. Cell viability was expressed as percentage of total LDH.

Determination of cell cycle distribution
----------------------------------------

Cells were washed with phosphate-buffered saline (PBS), trypsinized and pooled with the cells collected from corresponding suspension at the end of treatment. After washing once with PBS, cells were resuspended in citrate buffer (250 mM sucrose, 40 mM sodium citrate, pH 7.6). Cells were stained for 30 min in ice-cold DNA staining/lysis buffer (Mg^2+^ and Ca^2+^-free PBS containing 10µg/ml RNase, 20µg/ml propidium iodide, 0.5% NP-40, 0.5 mM EDTA, pH 7.2). Flow cytometric analysis was performed on a FACS Caliber (Becton Dickinson, Mountain View, CA) equipped with aircooled 488 nm argon-ion laser. Using a CELLQuest software (Becton Dickinson, Mountain View, CA), cell cycle distribution was analysed with a minimum of 10,000 cells.

Measurement of ONOO^-^-induced oxidation of dihydrorhodamine 123
----------------------------------------------------------------

The ONOO^-^-dependent oxidation of dihydrorhodamine 123 (DHR) to rhodamine 123 (RH) was measured, as described before ([@B8]). Briefly, SIN-1 (200µM) was added into phosphatebuffered saline solution (PBS) containing DHR (10 µM) in the absence and presence of etoposide. After a 10 min incubation at room temperature, the fluorescence of RH was measured at an excitation wavelength of 485 nm and emission wavelength of 530 nm (slit widths 20 and 25 nm, respectively) using a fluorescence microplate reader (FL600, Bio-tek Instruments, Inc., Winooski, VT).

Measurement of NO
-----------------

As previously described by us ([@B8]), the amount of NO was measured with a commercially available Clark-type electrode (ISO-NO, Mark II, World Precision Instruments, Sarasota, FL). NO is oxidized on the surface of a prepolarized working electrode, permeable only for gases with low molecular weights, resulting in electrical current. This current (pA) was recorded at 0.5 Hz and converted to a nM concentration of NO using a calibration curve that was generated daily. NO was released from 200µM S-nitroso-N-acetylpenicillamine (SNAP) by incubation in PBS containing 4 mM cysteine as a reducing agent and various concentrations of etoposide. All reagents were freshly prepared before use. The formation of NO was quantified from the initial rate of release using the data acquisition system Duo18 (World Precision Instruments, Sarasota, FL).

Measurement of superoxide anion
-------------------------------

As previously described by us ([@B8]), the amount of superoxide anion was monitored with a Berthold LB9505 luminometer (Bad Wildbad, Germany). The reaction mixtures contained 40 mU/ml xanthine oxidase, 5µM lucigenin, and various concentrations of etoposide in 1 ml of air-saturated PBS (pH 10). The superoxide-producing reaction was initiated by adding xanthine to yield a final concentration of 40µM. All reagents were freshly prepared in PBS. Chemiluminesence was measured at 1-min intervals for 10 min, and data are expressed as the integrated area under the 10-min curve. Mean blank values obtained by adding 300 U/ml SOD were subtracted from all chemiluminescent measurements.

Measurements of glutathione
---------------------------

For the measurement of glutathione (GSH), astrocytes were washed with PBS, and then incubated at 37℃ for 10 min with 50µM monochlorobimane. Cells were washed with PBS and then lysed with PBS containing 0.2% Triton X-100. The fluorescence of the monochlorobimane-GSH complex was measured with a fluorescence microplate reader (FL600, Bio-tek Instruments, Inc., Winooski, VT) (excitation wavelength of 400 nm and emission wavelength of 480 nm). The GSH content of the samples was calculated from the standard curve prepared from GSH standards incubated in the presence of monochlorobimane and glutathione transferase (Sigma Chemical Co., St. Louis, MO). The concentration of GSH was expressed as nmol/mg protein; protein content was determined using the bicinchoninic acid (Smith et al., 1985).

Measurement of hydrogen peroxide
--------------------------------

Hydrogen peroxide (H~2~O~2~) was measured spectrophotometrically with some modifications at 550 nm at 37℃ by the peroxydase-catalysed conversion of 4-aminophenazone to a pink-colored substance. Measurement was started after adding reagent to solution of various concentrations of etoposide and H~2~O~2~. This reagent consisted of 10 parts of solution A \[4.2 mM 3,5-dichloro-2-hydroxybenzenesulphonic acid, dissolved in Mops buffer (50 mM Mops/50 mM KCl, pH 7.4)\], 1 part of solution B (33 mM 4-aminophenazone) and 2.3 units/ml peroxydase (final activity).

Statistical analysis
--------------------

Data are expressed as the mean±standard error of mean (S.E.M.) and analysed for statistical significance using ANOVA followed by Scheffe\'s test for multiple comparison. A p value \<0.05 was considered significant.

RESULTS
=======

As we previously reported ([@B6]; [@B8]; [@B9]), SIN-1 potentiated the LDH release (i.e., a cell death marker) in glucose-deprived astrocytes ([Fig. 1](#F1){ref-type="fig"}). Presence of etoposide (10µM) 16 h before (i.e., pre-treatment) and during GD (i.e., co-treatment) completely blocked the potentiated cell death ([Fig. 1](#F1){ref-type="fig"}). Similarly, cotreatment of etoposide alone also blocked the increased cell death. However, FACS analysis using propidium iodide showed that co-treatment of etoposide alone did not arrest the cell cycle progression ([Table 1](#T1){ref-type="table"}). It implies that the cytoprotective effect of etoposide may not caused by its inhibition of cell cycle progression.

In brain, one of many well-known actions of astrocytes is to produce antioxidants, which scavenge reactive oxygen species and buffer oxidative stress. Astrocytes are known to be the main source of GSH which acts as a free radical scavenger and is important in recycling other antioxidants ([@B18]; [@B14]). Thus, astrocytes appear to be resistant to the actions of the strong oxidant ONOO^-^ ([@B2]). In the present study, the level of GSH in astrocytes was synergistically reduced by SIN-1 and GD ([Fig. 2A](#F2){ref-type="fig"}). Co-treatment of etoposide prevented the synergistic decrease of GSH ([Fig. 2A](#F2){ref-type="fig"}). Pretreatment of Lbuthionine-S,R-sulfoximine (BSO, a relatively specific inhibitor of GSH biosynthesis) for 16 h depleted the intracellular GSH ([Fig. 2B](#F2){ref-type="fig"}). Depletion of GSH itself did not induce the cell death, but increased the release of LDH in astrocytes exposed to SIN-1 or SIN-1/GD ([Fig. 2C](#F2){ref-type="fig"}). Although etoposide did not block the GSH depletion by BSO, it inhibited the increased peroxynitrite toxicity by BSO ([Fig. 2C](#F2){ref-type="fig"}).

The ONOO^-^ plays a critical role in the enhanced vulnerability of astrocytes to GD ([@B14]; [@B8]; [@B9]). To quantify the ONOO^-^ scavenging effect of etoposide, we used the dihydrorhodamine 123. We found that etoposide effectively inhibited ONOO^-^ (SIN-1)-induced oxidation of dihydrorhodamine 123 to rhodamine 123 in the presence of catalase ([Fig. 3A](#F3){ref-type="fig"}). However, etoposide was little or less efficacious in scavenging NO ([Fig. 3B](#F3){ref-type="fig"}) and O~2~^·-^ ([Fig. 3C](#F3){ref-type="fig"}).

Previously, we reported that GD increased the intracellular concentration of H~2~O~2~ in immunostimulated astrocytes, leading to astroglial cell death ([@B10]). Our present study showed that both GSH depletion and death in astrocytes simultaneously exposed to GD and H~2~O~2~ were not reversed by etoposide ([Fig. 4A](#F4){ref-type="fig"}, [B](#F4){ref-type="fig"}, respecively). We further found that etoposide did not effectively scavenge H~2~O~2~ ([Fig. 4C](#F4){ref-type="fig"}).

DISCUSSION
==========

Many researchers have used etoposide for experimentally inducing apoptosis in tumor cells. Studies on etoposide-induced apoptotic cell death include the processing of stabilized cleavage complexes into frank DNA strand breaks, sensing of the DNA damage, leading to activation of stress-asociated signaling pathways and cell cycle arrest ([@B16]; [@B20]; [@B22]). Etoposide can also activate a pre-existing group of enzymes and enzyme precursors, typified by the cysteine-dependent aspartate-directed protease (caspases) ([@B13]). The present study, however, demonstrates that the anti-tumoric DNA topoisomerase II inhibitor etoposide can reduce the peroxynitrite toxicity in glucose-deprived astrocytes by directly scavenging peroxynitrite, not by inhibiting cell cycle progression. Furtherore, etoposide interacts with ONOO^-^ most likely due to the high reactivity of ONOO^-^, but not with other products NO, O~2~^·-^ and H~2~O~2~.

The mammalian cell cycle maintains internal checkpoints at which cells are arrested when previous events have not been completed in response to external signals ([@B12]). The cell cycle checkpoints are thought to exist at the G1/S and G2/M transitions ([@B1]). Etoposide has been used as a potent and reversible blocker of the cell cycle that appears to act at the G2/M transition. Previously, we found that the G1/S transition blockers mimosine and ciclopirox also blocked the peroxynitrite toxicity. Like etoposide, mimosine reduced the augmented death of glucose-deprived immunostimulated astrocytes by directly scavenging peroxynitrite rather than suppressing the cell cycle progression ([@B8]). Unlike mimosine, however, ciclopirox blocked the peroxynitrite toxicity in glucose-deprived SIN-1-treated astrocytes by attenuating peroxynitrite-induced mitochondrial dysfunction, not by scavenging peroxynitrite ([@B9]; [@B17]). Ciclopirox neither prevented the depletion of reduced glutathione in glucose-deprived SIN-1-treated astrocytes, nor scavenged oxidants such as peroxynitrite, nitric oxide, superoxide anion, hydrogen peroxide and hydroxyl radical ([@B9]). Because of those various mechanisms of action, therefore, such cell cycle inhibitors should be carefully selected for the studies on oxidative stress-related cell deaths.
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![Etoposide inhibits the increased death in astrocytes simultaneously exposed to SIN-1 and GD. Astrocytes were exposed to 200µM SIN-1 and/or GD with or without pre- and co-treatment, or just co-treatment of etoposide. LDH levels were determined 6 h after starting the GD. Data are the percent of total LDH and expressed as the mean S.E.M. N=5. ^\*\*\*^p\<0.001, (two-way ANOVA followed by post-hoc Scheffe\'s test) significantly different from the untreated group.](en-19-90-g001){#F1}

![Etoposide inhibits the depletion of GSH in astrocytes simultaneously exposed to SIN-1 and GD. (A) Astrocytes were exposed to 200µM SIN-1 and/or GD with or without co-treatment of etoposide. GSH levels were measured 1 h after starting GD. Data are the percent of total LDH and expressed as the mean±S.E.M. N=6. ^\*\*\*^p\<0.001, (two-way ANOVA followed by post-hoc Scheffe\'s test) significantly different from the untreated control group. (B) Astrocytes were preincubated with 100µM L-BSO for 12 h and then incubated in various conditions. GSH levels were measured 1 h after starting GD in the absence and presence of 200µM SIN-1 and/or GD, and 10µM etoposide. (C) LDH levels were measured 6 h after starting of GD in the absence and presence of 200µM SIN-1 and/or GD, and 10µM etoposide. Data are the percent of total LDH and expressed as the mean±S.E.M. N=9. ^\*\*\*^p\<0.001, (two-way ANOVA followed by post-hoc Scheffe\'s test) significantly different from the untreated group.](en-19-90-g002){#F2}

![Etoposide scavenges peroxynitrite, but not NO and superoxide anion. (A) Peroxynitrite. Cells were loaded with DHR and then the fluorescence intensities were measured in the presence and absence of SIN-1 and/or etoposide. Data are expressed as fluorescence intensities (F.I.). (B) Nitric oxide. NO was generated from SNAP in the presence of various concentrations of etoposide (0.1 to 1 mM) and 4 mM cysteine as a reducing agent. The formation of NO was quantified from the initial rate of release using the data acquisition system Duo-18. (C) Superoxide anion. Production of O~2~^·-^ was initiated by adding xanthine (final concentration, 40µM) to the reaction mixtures described in the Materials and Methods section. Superoxide anion was generated in the presence of various concentration of etoposide (0.1 to 1 mM). All data were normalized by the mean blank values obtained by adding 300 U/ml SOD. Results were expressed mean±S.E.M. from 4 independent experiments. ^\*^p \<0.05, ^\*\*\*^p\<0.001, (two-way ANOVA followed by post-hoc Scheffe\'s test) significantly different from the value obtained in the absence of etoposide.](en-19-90-g003){#F3}

![(A) Etoposide does not inhibit the depletion of GSH in H~2~O~2~-treated astrocytes. Cells were exposed to H~2~O~2~ (100µM) and GD in the absence and presence of etoposide. GSH levels were measured at 30 min after starting GD in the absence and presence of 100µM H~2~O~2~. Data are expressed as the percent of untreated astrocytes. N=7. (B) Etoposide does not prevent the potentiated H~2~O~2~ toxicity in glucose-deprived astrocytes. Astrocytes were exposed to H~2~O~2~ (100µM) and GD in the absence and presence of etoposide for 2 h and then incubated in the culture medium. LDH levels were determined 6 h after starting GD. Data are the percent of total LDH and expressed as the mean±S.E.M. N=6. (C) Scavenging effect of etoposide on H~2~O~2~. Various concentrations of etoposide were incubated with H~2~O~2~ (100µM) for 15 min at room temperature. The amounts of H~2~O~2~ were spectrophotometrically measured at 550 nm. Data are expressed as the percent of control. N=5. ^\*^p\<0.05, ^\*\*\*^p\<0.001, (two-way ANOVA followed by post-hoc Scheffe\'s test) significantly different from the value obtained in the absence of etoposide.](en-19-90-g004){#F4}
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Changes of cell cycle distribution by etoposide. Astrocytes were exposed to 200 mM SIN-1 and/or glucose deprivation with or without pre-(16 h) and co-treatment, or just co-treatment of etoposide
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N=7. ^\*^p\<0.05, ^\*\*^p\<0.001, compared with the group simultaneously treated with SIN-1 and GD in the absence of etoposide.
